Best ever quarterly revenues at €7 million, +43% vs YAGO – Order backlog on June 30th 2022 at €60 million, +14.3% vs YAGO, and Cash Position of €28.2 million (€39 million on Dec. 31st, 2021), despite adverse conditions caused by the lockdown in ChinaRead more
News & events
Median will be exhibiting at the ECR, which will take place July 13-17 in Vienna. We will be so pleased to see you in person at our booth #AI-29, Expo X1, AI-area, to talk about the latest advancements of iBiopsy®, our AI-powered Software as Medical Device (SaMD). Happy to see you there!Visit conference website
iBiopsy® for Precision Medicine
Check out our paper published in the European Medical Journal on December 13, 2018 in order to educate the oncology specialists across Europe and the US as to the high-throughput artificial intelligence powered image-base phenotyping platform, iBiopsy® -> http://viewer.zmags.com/publication/647c38a3#/647c38a3/50
A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to improve precision medicine, is discussed in the presented review. The article introduces novel concepts, including high-throughput, fully automated imaging biomarker extraction; unsupervised predictive learning; large-scale content-based image-based similarity search; the use of large-scale clinical data registries; and cloud-based big data analytics to the problems of disease subtyping and treatment planning. Unlike electronic health record-based approaches, which lack the detailed radiological, pathological, genomic, and molecular data necessary for accurate prediction, iBiopsy® generates unique signatures as fingerprints of disease and tumor subtypes from target images. These signatures are then merged with any additional omics data and matched against a large-scale reference registry of deeply phenotyped patients. Initial applications targeted include hepatocellular carcinoma and other chronic liver diseases, such as nonalcoholic steatohepatitis. This new disruptive technology is expected to lead to the identification of appropriate therapies targeting specific molecular pathways involved in the detected phenotypes to bring personalised treatment to patients, taking into account individual biological variability, which is the principal aim of precision medicine.
Imaging Biomarkers vs Imaging Endpoints In clinical trials using imaging, biomarkers and response criteria are used to assess the tumor evolution with therapy. …Read more
This webinar is jointly organized by Labcorp Drug Development and Median Technologies. New Imaging biomarkers have a strong potential to provide additional insight for clinical trials: better selection of patients, prediction of response to therapy, early assessments of drug effects and safety. However, implementing them in clinical trials often promote challenges. The aim of this webinar is to discuss these challenges from the perspective of patients, physicians and the different stakeholders involved in the oncology clinical trials. During this webinar, you will learn:
- The value of modern imaging technologies in oncology trials
- The challenges linked to implementation of new imaging biomarkers
- How AI powered imaging optimizes clinical trial design
- Dr Yumin Zhang, Vice President and Chief Medical Officer, Huayi Technology CO LTD
- Dr Ravi Karra, M.D, Senior Medical Director Oncology, Labcorp Drug Development
- Dr Yan Liu, Chief Medical Officer, Median Technologies.